Millennium Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Millennium Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-71,470	Closed	-$182K	–	6952
2023 Q1	$182K	Sell	71,470 -497,098	-87%	-$982K	﹤0.01%	5211
2022 Q4	$1.06M	Buy	568,568 +274,469	+93%	+$684K	﹤0.01%	4105
2022 Q3	$756K	Sell	294,099 -210,122	-42%	-$523K	﹤0.01%	4579
2022 Q2	$973K	Buy	504,221 +346,050	+219%	+$755K	﹤0.01%	4395
2022 Q1	$470K	Buy	+158,171	New	+$595K	﹤0.01%	5171
2021 Q4	–	Sell	-22,313	Closed	-$108K	–	7580
2021 Q3	$108K	Sell	22,313 -227,472	-91%	-$1.25M	﹤0.01%	6406
2021 Q2	$1.7M	Buy	+249,785	New	+$2.02M	﹤0.01%	4150
2020 Q3	–	Sell	-11,627	Closed	-$61K	–	4934
2020 Q2	$61K	Sell	11,627 -4,948	-30%	-$22K	﹤0.01%	4034
2020 Q1	$52K	Sell	16,575 -17,196	-51%	-$63.4K	﹤0.01%	3663
2019 Q4	$136K	Buy	+33,771	New	+$117K	﹤0.01%	3961
2019 Q2	–	Sell	-209,760	Closed	-$1.12M	–	4600
2019 Q1	$1.12M	Buy	+209,760	New	+$1.35M	﹤0.01%	2792
2018 Q4	–	Sell	-14,281	Closed	-$139K	–	4304
2018 Q3	$139K	Sell	14,281 -101,207	-88%	-$1.02M	﹤0.01%	3701
2018 Q2	$1.18M	Buy	115,488 +32,984	+40%	+$373K	﹤0.01%	2734
2018 Q1	$1.07M	Sell	82,504 -213,118	-72%	-$3.17M	﹤0.01%	2652
2017 Q4	$5.29M	Sell	295,622 -38,731	-12%	-$808K	0.01%	1715
2017 Q3	$8.39M	Buy	334,353 +313,144	+1,476%	+$7.29M	0.01%	1349
2017 Q2	$511K	Sell	21,209 -490,746	-96%	-$10.8M	﹤0.01%	2795
2017 Q1	$9.86M	Buy	+511,955	New	+$8.07M	0.02%	1036
2016 Q4	–	Sell	-41,617	Closed	-$541K	–	3846
2016 Q3	$541K	Sell	41,617 -129,612	-76%	-$1.72M	﹤0.01%	2568
2016 Q2	$2.38M	Buy	+171,229	New	+$2.52M	0.01%	1691
2015 Q3	–	Sell	-38,286	Closed	-$987K	–	3815
2015 Q2	$987K	Buy	38,286 +16,872	+79%	+$479K	﹤0.01%	2292
2015 Q1	$669K	Buy	+21,414	New	+$615K	﹤0.01%	2566
2013 Q3	–	Sell	-3,000	Closed	-$109K	–	3645
2013 Q2	$109K	Buy	+3,000	New	+$129K	﹤0.01%	2861

Other funds holding PRTK

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Millennium Management's PRTK Position: Q2 2023 in Review

Millennium Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 71,470 shares — an estimated $182K sold.

Millennium Management first reported a position in PRTK in Q2 2013 and held it in 23 quarters. The position peaked at $9.86M in Q1 2017. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

Millennium Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Millennium Management sold 71,470 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $182K.
Millennium Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 23 quarters.
Millennium Management's Paratek Pharmaceuticals, Inc. position peaked at $9.86M in Q1 2017.
66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.